Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
-
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
-
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
-
This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month
-
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial — Update
-
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $32.60
- Day Range
- $30.43–32.48
- 52-Week Range
- $25.77–43.15
- Bid/Ask
- $30.66 / $30.71
- Shares Outstanding
- 125.69M
- Market Cap
- $3.83B
- Volume/Avg
- 7M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 65
Valuation
|
Metric
|
VKTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.72 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VKTX
|
|---|---|
Quick Ratio | 4.57 |
Current Ratio | 4.72 |
Interest Coverage | — |
Quick Ratio
VKTX
Profitability
|
Metric
|
VKTX
|
|---|---|
Return on Assets (Normalized) | −72.88% |
Return on Equity (Normalized) | −81.35% |
Return on Invested Capital (Normalized) | −85.30% |
Return on Assets
VKTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$vtz^g | LOCK|!n%bC | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>@>ZMTH | LOCK|P?%n? | $76B | |||
| Moderna Inc
MRNA
| LOCK|$Mkm!& | LOCK|XZ | $75B | |||
| argenx SE ADR
ARGX
| LOCK|<Jc>bQ? | LOCK|^$& | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$XjZHqD | LOCK|## | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&#j!&S | LOCK|wFl#! | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|R?nRDwf | LOCK|P<wMr | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|%RkhX^ | LOCK|tg | $24B | |||
| Incyte Corp
INCY
| LOCK|v<r&tcM | LOCK|#VQ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j#mKLt? | LOCK|>X@ | $15B |
United States